Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 11:15:17562848221101722.
doi: 10.1177/17562848221101722. eCollection 2022.

SARS-CoV-2-inactivated vaccine hesitancy and the safety in inflammatory bowel disease patients: a single-center study

Yubin Cao  1 , Jiaming Feng  2 , Shihao Duan  1 , Yi Yang  1 , Yan Zhang  3
Affiliations

SARS-CoV-2-inactivated vaccine hesitancy and the safety in inflammatory bowel disease patients: a single-center study

Yubin Cao et al. Therap Adv Gastroenterol. .

Abstract

Background: The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine is thought to be the most effective preventive method of controlling the coronavirus disease 2019 (COVID-19) epidemic. Some patients with immune-related diseases, including inflammatory bowel disease (IBD) patients, however, may hesitate to be vaccinated for various reasons. Although several guidelines recommend vaccinating all IBD patients with inactivated SARS-CoV-2 vaccines, there is still a lack of real-world data on the safety of inactivated SARS-CoV-2 vaccines and COVID-19 vaccination rate in IBD patients. In this study, we investigated the reasons for hesitancy in COVID-19 vaccination, the COVID-19 vaccination rate, and the safety of SARS-CoV-2-inactivated vaccination in patients with IBD.

Methods: This was a retrospective study. A total of 418 participants with IBD were enrolled to calculate the vaccination rates. A total of 232 patients with IBD who did not receive SARS-CoV-2 vaccination were recruited to investigate the reasons for hesitation. A follow-up survey of 151 IBD patients and 188 healthy participants who had received the SARS-CoV-2-inactivated vaccination was conducted to analyze adverse reactions.

Results: The COVID-19 vaccination rate was 49.3% and almost half of the participants were 'Concerned about the safety of the vaccine (such as adverse reactions) due to IBD'. After SARS-CoV-2 vaccination, adverse reactions were mild or moderate. The adverse reactions in the IBD and non-IBD populations were roughly the same, and IBD medications did not increase the risk of adverse reactions.

Conclusion: SARS-CoV-2-inactivated vaccination rates in IBD patients are still low and a significant proportion of patients are hesitant about the vaccine because of safety concerns. SARS-CoV-2-inactivated vaccination in patients with IBD appears to be safe.

Keywords: COVID-19; IBD; SARS-CoV-2-inactivated vaccination.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Study profile.
See this image and copyright information in PMC

References

    1. World Health Organization (WHO): coronavirus disease (COVID-19) dashboard 2021, https://covid19.who.int/
    1. Rahier J-F, Moutschen M, Van Gompel A, et al. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology 2010; 49: 1815–1827. - PMC - PubMed
    1. Macaluso FS, Liguori G, Galli M. Vaccinations in patients with inflammatory bowel disease. Digest Liver Disease 2021; 53: 1539–1545. - PubMed
    1. Callaway E. The race for coronavirus vaccines: a graphical guide. Nature 2020; 580: 576–577. - PubMed
    1. Mao Q, Xu M, He Q, et al. COVID-19 vaccines: progress and understanding on quality control and evaluation. Signal Transduct Target Ther 2021; 6: 199. - PMC - PubMed

LinkOut - more resources